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Abstract
Background: The BRAF
V600E mutation leading to constitutive signaling of MEK-ERK pathways causes papillary thyroid cancer
(PTC). Ras association domain family 1A (RASSF1A), which is an important regulator of MST1 tumor suppressor pathways, is
inactivated by hypermethylation of its promoter region in 20 to 32% of PTC. However, in PTC without RASSF1A methylation,
the regulatory mechanisms of RASSF1A-MST1 pathways remain to be elucidated, and the functional cooperation or cross
regulation between BRAF
V600E and MST1,which activates Foxo3,has not been investigated.
Methodology/Principal Findings: The negative regulators of the cell cycle, p21 and p27, are strongly induced by
transcriptional activation of FoxO3 in BRAF
V600E positive thyroid cancer cells. The FoxO3 transactivation is augmented by
RASSF1A and the MST1 signaling pathway. Interestingly, introduction of BRAF
V600Emarkedly abolished FoxO3
transactivation and resulted in the suppression of p21 and p27 expression. The suppression of FoxO3 transactivation by
BRAF
V600Eis strongly increased by coexpression of MST1 but it is not observed in the cells in which MST1, but not MST2,is
silenced. Mechanistically, BRAF
V600Ewas able to bind to the C-terminal region of MST1 and resulted in the suppression of
MST1 kinase activities. The induction of the G1-checkpoint CDK inhibitors, p21 and p27,by the RASSF1A-MST1-FoxO3
pathway facilitates cellular apoptosis, whereasaddition of BRAF
V600E inhibits the apoptotic processes through the
inactivation of MST1. Transgenic induction of BRAF
V600Ein the thyroid gland results in cancers resembling human papillary
thyroid cancers. The development of BRAF
V600Etransgenic mice with the MST1 knockout background showed that these
mice had abundant foci of poorly differentiated carcinomas and large areas without follicular architecture or colloid
formation.
Conclusions/Significance: The results of this study revealed that the oncogenic effect of BRAF
V600E is associated with the
inhibition of MST1 tumor suppressor pathways, and that the activity of RASSF1A-MST1-FoxO3 pathways determines the
phenotypes of BRAF
V600E tumors.
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Introduction
Activating mutations in the BRAF gene are found at high
frequency in various human cancers, and BRAF
V600E is the most
common of these activating mutations, especially in papillary
thyroid cancer, where it is found at a frequency of 40–70% [1,2,3].
In BRAF
V600E-positive thyroid cancer cell lines and BRAF
V600E
transgenic mice, this mutation is responsible for tumor initiation,
transformation, growth, proliferation and dedifferentiation [4,5,6].
Research into the molecular mechanisms of BRAF
V600E-positive
tumors has revealed that the missense valine to glutamic acid
mutation increases kinase activity, promoting the constitutive
activation of MEK-ERK signaling [7,8,9,10,11] and enhancing
ERK-dependent transcriptional output [12,13]. However, other
signaling pathways except MEK-ERK [14,15]regulated in
BRAF
V600E tumors are not fully characterized [16]. Moreover,
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16180tumor suppressor systems which may be controlled by BRAF
V600E
in thyroid cancer remain to be identified.
The tumor suppressor gene RASSF1A (Ras association domain
family 1A) is epigenetically inactivated through de novo promoter
methylation in the early stages of thyroid tumorigenesis [17,18].
Interestingly, RASSF1A has recently been described as an important
activator of MST1, which in turn phosphorylates and promotes the
nuclear translocation of the forkhead transcription factor FKHRL1
(FoxO3), inducing cell death [19,20,21]. This suggests that FoxO3
transactivation could be induced by the RASSF1A-MST1 pathway
and function as a tumor suppressor system in response to specific
oncogenic signals, such as BRAF
V600E. However, promoter hyper-
methylation of RASSF1A could only be detected in a relatively small
percentage of PTC (20 to 32%) [18,22]. These observations predict
that novel RASSF1A-MST1-FoxO3 pathways regulated by
BRAF
V600E might function during the development of PTC
whichdoes nothave RASSF1Apromoter methylation.
FoxO3 transactivation is effectively inhibited by RET/PTC
(rearranged in transformation/papillary thyroid carcinomas)
kinase [23], the gene rearrangement of which is the most common
rearrangement in papillary thyroid cancer. The inactivation of
FoxO3 could therefore be a signature molecular event that should
also occur in BRAF
V600E thyroid tumors. Several molecular
mechanisms which are possibly regulated by BRAF
V600E may
control FoxO3 activity in thyroid cancer. First, as RET/PTC
kinase inhibits FoxO3 transactivation through an Akt/PKB
dependent pathway, BRAF
V600E might also activate Akt/PKB
signaling pathway [24]. Second, the constitutive activation of ERK
by BRAF
V600E could inhibit FoxO3 activation via the ubiquitin-
proteasome pathway [25]. Finally, BRAF
V600E could act through
crosstalk with the RASSF1A-MST1-FoxO3 pathway.
Based on these hypotheses, we decided to investigate the
regulation of the MST1-FoxO3 pathway by BRAF
V600E. This
resulted in the identification of novel cross-talksignaling between
BRAF
V600E and MST1, thereby demonstrating the functional
activity of the RASSF1A-MST1-FoxO3 tumor suppressor system.
Furthermore, in vivo experiments showed that MST1 knockout




The pCMV5-Myc-FoxO3 plasmid was purchased from Addgene
(Addgene Inc., Cambridge, MA) and pcDNA3.1/CT-GFP-FoxO3
was constructed using the CT-GFP Fusion TOPO Expression Kit
according to the manufacturer’s protocol (Invitrogen, Carlsbad, CA).
Expression vectors (pME18) for Flag epitope-tagged forms of human
MST1, MST1-N (residues 1–326), MST1-C (residues 327–487),HA-
RASSF1A and 3X-IRS reporters have been described previously
[26,27,28,29]. The cDNA for human BRAF was cloned into
pLenti6/V5-DEST using the pDONR221 vector (Invitrogen). For
the cloning of BRAF, PCR primers were designed as follows: sense,
59-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCAAGAT-
GGCGGCGCTGAGCGGT-39, and antisense, 59- GGGGACC-
ACTTTGTACAAGAAAGCTGGGTCTCAGTGGACAGGAA-
ACGCCC-39. To generate vectors for human BRAF
V600E and
BRAF
G469A, the Site-Directed PCR Mutagenesis Kit (Stratagene, La
Jolla, CA) was used to introduce the missense mutation into the wild-
type BRAF sequence. SiRNAs for MST1 and RAF-1 werepurchased
from Invitrogen (Stealth RNAi, Invitrogen).
Cell culture and transfection
FRO cells and 293T cells were cultured in RPMI and DMEM
supplemented with 10% fetal bovine serum [20,30]. Cells (2610
5/
35 mm dish) were transfected with siRNA at a concentration of
50 nM using the HiPerfect Transfection Reagent (Qiagen, Valencia,
CA) and/or with the indicated vectors using Fugen6 Transfection
Reagent (Roche Applied Science,I n d i a n a p o l i s ,I N ) .T h eM E K
inhibitor (U0126) and PI3K inhibitors (Ly294002, Wortmannin)
were purchased from Cell Signaling Technology (Beverley, MA).
Antibodies
Primary antibodies against p21, p27, phospho-ERK, total
ERK, phospho-Akt, total Akt, MST1, Actin, FoxO3, Myc (Cell
Signaling), BRAF (C-19, Santa Cruz Biotechnology, Santa Cruz,
CA), RASSF1A (eBioscience, San Diego, CA) and Flag (Sigma, St
Louis, MO) were purchased from the indicated companies.
Luciferase-based reporter assay
To assay the activity of FoxO3, 293T cells were transfected with
3X-IRS-Luc, or p27-Luc and pRL-SV40, which encodes Renilla
luciferase (Promega, Madison, WI) using Lipofectamine in
OptiMEM (Invitrogen). Luciferase levels were determined using
the Dual Luciferase Assay Kit (Promega). Firefly and Renilla
luciferase activities were measured sequentially from the same
sample using a Fusion Alpha-Microplate Analyzer (Perkin Elmer,
Waltham, MA). For each sample, firefly luciferase activity was
normalized to Renilla luciferase activity.
Immunoprecipitation and Immunoblot analysis
All immunoprecipitation and immunoblotting procedures were
performed at 4uC. Cells were washed twice with PBS and lysed in
lysis buffer containing protease inhibitors. Lysates were centrifuged
at 14,000 g for 15 min at 4uC. For the IP analysis, lysates were
precleared with protein A/G beads (Santa Cruz Biotechnology) for
30 min, and supernatants were incubated with the indicated
primary antibody for 3 h with agitation. Protein A/G beads were
then added to the mixture and incubated for at least 2 h at 4uC.
Beads were washed with lysis buffer and the immunoprecipitates
were subjected to immunoblotting. Cell lysates were separated by
SDS-PAGE, and transferred to nitrocellulose membranes. Mem-
branes were blocked with TBS containing 5% milk and 0.1%
Tween20 for 1 h and then incubated overnight with primary
antibody at 4uC. Membranes were washed in TBS/T and
incubated with secondary antibodies conjugated to horseradish
peroxidase (Cell Signaling) for 1 h at RT. Blots were developed
using the LumiGLOChemiluminescent substrate (Cell Signaling).
Immunofluorescence staining
293T cells were grown on 6-well plates and transfected with the
indicated plasmids using LipofectAmine (Invitrogen). Twenty-four
hours after transfection, the cells were washed three times with
PBS and fixed in 3.7% formaldehyde for 20 min. Cells were
permeabilized with PBS containing 0.1% Triton X-100 and 0.1 M
glycine at RT, incubated for 15 min, washed three times with
PBS, and blocked with 3% BSA in PBS for 10 min at RT. Cells
were incubated with primary anti-Myc and anti-Flag for 1 h at
37uC, washed three times with PBS, and incubated for 1 h at 37uC
with Cy5-conjugated anti-Rabbit and TRITC-conjugated anti-
Mouse for Myc-BRAF
V600E and Flag-MST1, respectively (Jackson
ImmunoResearch Laboratories, West Grove, PA). Cells were
observed with a CellomicsArrayScanV HCS reader (Thermo
Scientific, Pittsburgh, PA).
In vitro kinase assay of MST1
MST1 was immunoprecipitated from cell lysates and the
washed precipitates were incubated for 30 minutes at 30uC with
Cross-Regulation between MST1 and BRAF
V600E
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e161801 mg histone H2B (Roche) in 25 mL kinase assay buffer comprised
of 40 mM HEPES-NaOH (pH 7.4), 20 mM MgCl2, 1 mM DTT,
phosphatase inhibitor mixture, 10 mM unlabeled ATP, and 1 mCi
[c-32P]ATP. The reaction was terminated by the addition of
Laemmli sample buffer and phosphorylated proteins were
detected by SDS-PAGE followed by autoradiography.
Apoptosis Assay
Image based apoptosis assays were carried out using the APO-
BrdU TUNEL Assay Kit (Invitrogen). Cells was transfected with
FoxO3, MST1, and/or BRAFV
600E, as indicated, and then
stained with DAPI and terminal deoxynucleotidyltransferase–
mediated dUTP nick end labeling (TUNEL) reagents.The
proportion of apoptotic cells was determined asthe percentage of
TUNEL-positive cells among all DAPI-stainedcells.
Mouse Experiments and Histology
The strategy and methods used for the generation of thyroid
specific transgenic BRAF
V600E FVB/N mice with a bovine
thyroglobulin promoter have been described previously [4]. A
detailed explanation of how MST1 null mice are generated is
described in a recent paper from our group [31]. The MST1-null
mice appeared to have normal reproductive capacity when
compared with wild-type mice. Tg-BRAF
V600E mice were crossed
with MST1-null mice to obtain Tg-BRAF
V600E/MST1-null mice
and Tg-BRAF
V600E littermates. These mice were sacrificed at 16
weeks and their thyroids were removed after genotyping. Thyroid
tissues were fixed in 10% formalin and embedded in paraffin. Five
mM-thick sections were prepared and stained with H&E.
Immunohistochemical analysis of paraffin embedded thyroid
tissue was also performed using anti-cyclin D1 rabbit monoclonal
antibody (92G2, Cell Signaling). ImageJ (http://rsbweb.nih.gov/
ij/) for microscopy was used to estimate areas without follicular
architecture or colloid formation in thyroid tissues. Tg-
BRAF
V600E/MST1 null mice (n=10) and Tg-BRAF
V600E litter-
mates (n=10) were collected and three sections of each mouse
were used for immunohistochemical and imageJ analysis.
Differences in the number of undifferentiated foci and areas
without follicular architecture or colloid formation between both
groups were assessed by the Mann-Whitney U-test. All animal
experiments were approved by the Institutional Animal Care and
Use Committee of the Chungnam National University School of
Medicine (Approval ID; 2009-3-25).
Statistical Analysis
Results were expressed as the means 6 standard deviations.
Statistical differences between two groups were analyzed by the
Mann-Whitney U test. Differences were considered to be
significant at P,0.05.All statistical analyses were performed using
SPSS Version 16.0 for Windows (SPSS Inc., Chicago, IL).
Results
BRAF
V600E suppresses p21 and p27 induction by RASSF1A
in FRO cells
To confirm that RASSF1A induces FoxO3 transactivation,
RASSF1A was transiently transfected into FRO cells harboring
the BRAF mutated alleles and then p21 and p27, the known
transcriptional targets of FoxO3, were assessed by immunoblotting
[30]. As shown in Fig 1A, endogenous RASSF1A was not
detected, which is compatible with previous reports showing
hypermethylation of RASSF1A in undifferentiated thyroid cancer
cell lines [17,32]. Fig. 1A shows the RASSF1A-induced dose
dependent increase in p21 and p27, which suggests that RASSF1A
might be linked with FoxO3 transactivation. To investigate the
possible crosstalk between RASSF1A and BRAF
V600E, the effect of
BRAF
V600E on RASSF1A-mediated p21 and p27 induction was
evaluated. Interestingly, BRAF
WT did not affect the induction of
p21 and p27 by RASSF1A, whereas BRAF
V600E effectively
decreased p21 and p27 (Fig. 1B), suggesting that oncogenic
BRAF
V600E can regulate the RASSF1A-FoxO3 signaling pathway.
As BRAF
V600E can inhibit FoxO3 transactivation via the ERK or
Figure 1. BRAF
V600E suppresses p21 and p27 induction by RASSF1A in FRO cells. (a) FRO Cells were transfected with HA-RASSF1A as
indicated and incubated for 24 h. Total lysates were analyzed for p21 and p27 expression by Western blot analysis. (b) Lysates from FRO cells co-
transfected with vectors for HA-RASSF1A and BRAF (wild type or the V600E mutant), as indicated, were subjected to Western blot analysis. (c) FRO
cells transiently transfected with BRAF
V600E and RASSF1A were incubated with MEK (U0126, 10 mM) or PI3K (wortmannin, 1 mM, Ly294002, 10 mM)
inhibitors for 12 h as indicated. The lysates were subjected to western blot analysis with primary antibodies as indicated. (d) FRO cells co-transfected
with RASSF1A (0.5 mg/well) and SiMST1 (20 mM/well Stealth
TM RNA) were incubated for 24 hrs as indicated. Abbreviations: CTL; control.
doi:10.1371/journal.pone.0016180.g001
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PI3K inhibitors (Wortmannin, LY294002) were used to block
these pathways and observe the effect of BRAF
V600E on
RASSF1A-induced FoxO3 transactivation. As shown in Fig. 1C,
the BRAF
V600E-mediated suppression of p21 and p27 induction by
RASSF1A was not reversed by the MEK inhibitor U0126 or the
PI3K inhibitors Wortmannin and LY294002, showing that
BRAF
V600E inhibits the RASSF1A-induced p21 and p27 upregu-
lation independently from the ERK and PI3K-Akt/PKB signaling
pathways. Recently, RASSF1A was shown to interact with MST1
via its SARAH domain and increase MST1 kinase activity [20],
suggesting that RASSF1A-MST1-FoxO3 might be operational in
response to oncogenic signals. To verify this hypothesis, MST1
expression was silenced using siRNA, and the RASSF1A induction
of p21 and p27 was assessed. Fig. 1D shows that RASSF1A did not
induce p21 and p27 expression in siMST1-treated cells, indicating
that MST1 plays an important role in the p21 and p27 induction
by RASSF1A.
BRAF
V600E represses FoxO3 transactivation by the
RASSF1A-MST1 signaling pathway
The transcriptional activity of FoxO3 is regulated by posttrans-
lational modifications such as phosphorylation, acetylation,
nitrosylation and sumoylation [33,34,35].Among these modifica-
tions, the MST1-mediated serine 207 phosphorylation of FoxO3 is
critical for its nuclear translocation [19,36]. To investigate whether
the RASSF1A-MST1 signal increased FoxO3 transactivation, a
3XIRS reporter system was used, consisting of a 3XIRS promoter
construct containing three insulin response sequences/FoxO
response elements (CAAAA[C/T]AA, the 3XIRS promoter)
[26,29]. Transient expression of MST1 significantly increased
3XIRS reporter activities in a dose-dependent manner (Fig. S1).
Evaluation of the effect of RASSF1A on FoxO3 reporter activity
showed that RASSF1A remarkably increased 3XIRS reporter
activity (Fig. 2A). Moreover, this RASSF1A-induced FoxO3
reporter activation was completely abolished by MST1 silencing,
indicating that RASSF1A effectively increased FoxO3 transactiva-
tion through a MST1-dependent pathway (Fig. 2B).
Because BRAF
V600E inhibited RASSF1A-induced p21 and p27
upregulation, the effect of BRAF
V600E on FoxO3 transactivation
by RAASF1A was assessed. As shown in Fig. 2C, BRAF
V600E
abrogated the RASSF1A-induced FoxO3 transactivation. Fur-
thermore, MST1-induced FoxO3 transactivation was also re-
pressed by BRAF
V600E, indicating that BRAF
V600E inhibits the
RASSF1A-MST1-FoxO3 pathway (Fig. 2D).
Because the transcriptional activity of FoxO3 depends on its
nuclear translocation, a FoxO3-GFP vector was constructed to
confirm the data obtained with the 3XIRS reporter by
immunofluorescence imaging. As shown in Fig. 2E, GFP-
fluorescence was predominantly observed in the cytoplasm in
control samples; introduction of MST1 caused a shift in GFP-
fluorescence detection to the nucleus. When BRAF
V600E was co-
transfected with MST1, nuclear GFP fluorescence was barely
detected. Interestingly, BRAF
V600E was exclusively localized in the
cytoplasm (blue), MST1 showed dominant cytoplasmic localiza-
tion (red), and merged images revealed a combined color (lilac)
that suggests the co-localization of BRAF
V600E and MST1. To
quantify FoxO3-fluorescence, the nuclear GFP-fluorescence signal
intensity was analyzed using the BioApplication of CellomicsAr-
rayScan, following the manufacturer’s protocol. In agreement with
the immunofluorescence images, MST1 increased intensity of the
nuclear GFP-fluorescence signal, and BRAF
V600E inhibited the
nuclear detection of GFP-fluorescence (Fig. 2F). Furthermore, we
performed fractionation assay to define the subcellular localization
of FoxO3-GFP and observed that MST1 increased nuclear
FoxO3-GFP and BRAF
V600E could reverse this MST1-induced
FoxO3 nuclear localization (Fig. S2).Taken together, these results
indicate that BRAF
V600E inhibits nuclear translocation of FoxO3




V600E represses FoxO3 transactivation via MST1
kinase-dependent pathway
RAF-1 is an homologue of BRAF that interacts with MST2,
suppressing MST2-mediated apoptosis [37,38], which may be
important for the regulation of certain biological processes [39]. In
our study, however, FoxO3 inhibition by BRAF
V600E was not
altered by RAF-1 silencing (Fig. S3). Furthermore, this inhibitory
effect of BRAF
V600E was not reversed by the inhibition of MEK or
PI3-kinase (Fig. S4), confirming that BRAF
V600E is able to
suppress FoxO3 transactivation through a mechanism indepen-
dent from MEK/ERK and PI3-kinase signaling.
The inhibition of RASSF1A or MST1-induced FoxO3
transactivation and nuclear translocation by BRAF
V600Eled to
the hypothesis that BRAF
V600E might regulate FoxO3 transactiva-
tion via a MST1-dependent pathway. To verify this hypothesis,
reporter experiments were carried out in siMST1-treated cells.
Remarkably, following knockdown of MST1, FoxO3 could not
induce full activation of the 3XIRS reporter and BRAF
V600E no
longer had an effect on FoxO3 induced activation of 3XIRS
reporter (Fig. 3A). These observations suggest that MST1 plays a
role in FoxO3 transactivation and that BRAF
V600E inhibits FoxO3
transactivation by suppressing MST1 activity. The reporter assay
was also used to test whether there is signal-crosstalk between
MST1 and BRAF
V600E on FoxO3 transactivation. As expected,
BRAF
V600E inhibited MST1-induced 3XIRS reporter activation
in a dose-dependent manner and MST1 abolished the inhibitory
effect of BRAF
V600E on FoxO3 transactivation (Fig. 3B & 3C).
These reporter assays indicated that increased levels of MST1
could prevent BRAF
V600E-induced FoxO3 inactivation. Taken
together, these data suggest that the cross-regulation between
BRAF
V600E and MST1 determines the degree of FoxO3
transactivation.
BRAF
V600E shows mutation-specific binding with the C-
terminal of MST1 and inhibits MST1 kinase activity in vitro
Because immunofluorescence images and reporter assays
suggested that BRAF
V600E and MST1 might be colocalized and
have competitive effects on FoxO3 transactivation, immunopre-
cipitation (IP) assays were carried out to define the direct
interaction of BRAF
V600E and MST1. As shown in Fig. 4A,
BRAF
V600E was co-precipitated with Flag-tagged MST1 in lysates
from 293T cells transfected with BRAF
V600E and Flag-tagged
MST1 and vice versa. To verify the region of MST1 important for
the interaction with BRAF
V600E, IP assays using MST1 deletion
constructs, such as MST1 N-terminal (residues 1–326) and C-
terminal (327–487) constructs (Fig. 4B), were carried out. These IP
assays consistently demonstrated that BRAF
V600E binds to the C-
terminal region of MST1 (Fig. 4C), which contains of regulatory
binding domain with the Sav/RASSF1/Hpo (SARAH) domain of
RASSF1A [40,41,42]. To verify theBRAF
V600Emutation specific
binding with MST1, we performed additional IP assays using
BRAF
WT and BRAF
V600E constructs. Furthermore, as shown in
Fig. 4D, BRAF
V600Ewas consistently co-precipitated with Flag-
tagged MST1 whereas wild-type BRAF did not. Taken together,
these results show that BRAF
V600E can bind to the C-terminal
domain of MST1 via mutation-specific protein-protein interaction.
Cross-Regulation between MST1 and BRAF
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and increases MST1 kinase activity, the interaction between
BRAF
V600E and MST1 might affect MST1 kinase activity by
interrupting the heterotypic interaction of MST1 with RASSF1A.
To verify this, the effect of BRAF
V600E on the kinase activity of
MST1 was examined in vitro using 293T cells, which were
transfected with Flag-MST1 and BRAF
V600E as indicated. The
immunoprecipitates obtained with an antibody to Flag were used
to assay for MST1 kinase activity using histone H2B as a substrate.
As seen in Fig. 4E, the expression of BRAF
V600E completely
abolished MST1 kinase activity. These data suggest that
BRAF
V600E can negatively regulate MST1 kinase through direct
interaction with its C-terminus.
BRAF
V600E generates an anti-apoptotic effect via
repression of p21 and p27 induction
FoxO3 acts as a cell-cycle regulator by inducing the
transcription of genes such as p21 and p27 [43], the promoters
of which contain IRS elements. The results of the assessment of
the regulatory effect of BRAF
V600E on the p27 reporter are shown
in Fig. 5A. FoxO3 increased p27 reporter activity and MST1
potentiated this FoxO3-induced p27 activation. In addition,
MST1-FoxO3 mediated p27 reporter activation was abrogated
by co-transfection with BRAF
V600E. To confirm that BRAF
V600E
can affect p27 reporter activity, the inhibitory effect of BRAF
V600E
on p21 and p27 induction was investigated by Western blot
analysis (Fig. 5B). The results confirmed the MST1-FoxO3
Figure 2. BRAF
V600E represses FoxO3 transactivation induced by RASSF1A-MST1 signal. 293T cells were transfected as indicated and
luciferase-based reporter assays were conducted to observe 3XIRS reporter activity. For each sample, firefly luciferase activity was normalized to
Renilla luciferase activity and expressed as the relative-fold change compared to basal luciferase activity. (a) Co-transfection with 3X-IRS Luc (100 ng/
well), FoxO3 (0.5 mg/well), and RASSF1A (0.5 mg/well) was performed as indicated, and incubation lasted for 24 h. Total lysates were immunoblotted
with anti-Myc, anti-HA, or anti-Actin antibodies. (b) Co-transfection with 3XIRS Luc (100 ng/well), FoxO3 (0.5 mg/well), RASSF1A (0.5 mg/well), and
SiMST1 (20 mM/well Stealth
TM RNA) was performed as indicated, and incubation lasted for 24 h. Total lysates were immunoblotted with anti-Myc,
anti-HA, anti-MST, or anti-Actin antibodies. (c) Co-transfection with 3X-IRS Luc (100 ng/well), FoxO3 (0.5 mg/well), RASSF1A (0.5 mg/well), and
BRAF
V600E (0.5 mg/well) was performed as indicated, and incubation lasted for 24 hours. Total lysates were immunoblotted with anti-Myc, anti-HA,
anti-BRAF, or anti-Actin antibodies. (d) Co-transfection with 3X-IRS Luc (100 ng/well), MST1(0.5 mg/well), and BRAF
V600E (0.5 mg/well) was performed
as indicated, and incubation lasted for 24 hours. All data are presented as mean6SD. Total lysates were immunoblotted with anti-Flag, anti-BRAF, or
anti-Actin antibodies. (e) BRAF
V600E inhibits MST1-induced nuclear translocation of FoxO1. 293T cells were cultured in a six-well dish until they
reached 80% confluence and co-transfected with FoxO3-GFP (0.5 mg/well), Flag-MST1 (0.5 mg/well), and Myc-BRAF
V600E (0.5 mg/well) as indicated.
Twenty-four hours after transfection, the cells were fixed and incubated with antibodies against Myc or Flag, washed, and incubated with Cy5-
conjugated anti-Rabbit for Myc-BRAF
V600E and TRITC-conjugated anti-Mouse for Flag-MST1. (f) Fluorescence was observed using a Cellomics
ArrayScanV HCS reader. To calculate FoxO3 distribution, at least one thousand cells in each experiment were counted and analyzed by Cellomics
BioApplication. All data are presented as mean6SD: (*) P,0.01 between two groups, Abbreviations: CTL; control.
doi:10.1371/journal.pone.0016180.g002
Cross-Regulation between MST1 and BRAF
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by BRAF
V600E co-transfection. Notably, these two G1-checkpoint
CDK inhibitors have been associated with the initiation and
progression of human tumors because p21 and p27 bind and
inhibit cyclin-CDK complexes, inducing cell cycle arrest and
apoptosis. Therefore, the TUNEL assay was used to determine
whether MST1-FoxO3 promotes apoptosis and if BRAF
V600E
reverses the MST1-FoxO3 effect (Fig. 5C). Transient co-
expression of FoxO3 and MST1 increased the number of TUNEL
positive 293T cells, but this number was decreased by the
introduction of BRAF
V600E (see also right panel of Fig. 5C for
statistical analysis). These results imply that the MST1-FoxO3
pathway induction of G1-checkpoint CDK inhibitors promotes
apoptosis, and oncogenic BRAF
V600E inhibits the activity of these
tumor suppressor systems through the regulation of MST1.
Loss of MST1 aggravates PTC phenotypes in thyroid-
specific transgenic BRAF
V600E mice
To validate the pathophysiological consequences of the
interaction between BRAF
V600E and MST1 in vivo, animal
experiments using thyroid-specific transgenic BRAF
V600E mice
(Tg-BRAF
V600E mice) and MST1 null mice were designed. Tg-
BRAF
V600E mice were crossed with MST1 null mice and the
phenotypic differences between Tg-BRAF
V600E/MST1 null mice
and their Tg-BRAF
V600E littermates were analyzed at 16 weeks
[4]. The thyroid glands of MST1 null mice with wild-type BRAF
were normal (data not shown). However, Tg-BRAF
V600E/MST1
null mice showed aggressive PTC tumor phenotypes compared
with their Tg-BRAF
V600E littermates. Although the presence of
lymph node metastasis was not observed in either of the two
groups, Tg-BRAF
V600E/MST1 null mice showed abundant foci of
undifferentiated carcinomas and large areas without follicular
architecture or colloid formation (Figure 6A–H). For the statistical
analysis of these results, immunohistochemical staining of cyclin
D1 was performed, which showed an intensive cyclin D1 staining
area as undifferentiated foci (Fig. 6B&C, F–G). As shown in
Figure 6D, the number of undifferentiated foci in female Tg-
BRAF
V600E/MST1 null mice was 3.360.86, but that of their Tg-
BRAF
V600E littermates was 1.0560.51, reflecting a statistical
difference between the two groups (P,0.001). Similarly, male Tg-
BRAF
V600E/MST1 null mice showed a higher number of
undifferentiated foci than their Tg-BRAF
V600E littermates
(3.560.83and 1.3560.67, respectively; P,0.001). The total area
composed of sheets of spindle cells without follicular architecture
or colloid formation was estimated and ImageJ (http://rsbweb.
nih.gov/ij/) was used to quantify these areas and analyze the
differences between Tg-BRAF
V600E/MST1 null mice and their
Tg-BRAF
V600E littermates (Figure 6H). In female mice, Tg-
BRAF
V600E/MST1 null mice had a significantly larger area
without follicular architecture or colloid formation than their Tg-
BRAF
V600E littermates (75.4763.83% and 52.6967.93%, respec-
tively; P=0.034). In male mice, Tg-BRAF
V600E/MST1 null mice
also showed a larger area without follicular architecture or colloid
formation compared to their Tg-BRAF
V600E littermates
(70.0263.68% and47.3167.93%, respectively; P=0.021). This
in vivo study suggests that the direct interaction between
BRAF
V600E and MST1 could affect the behavior of papillary
thyroid cancer. Another piece of evidence demonstrating the
aggressive tumor phenotype in these Tg-BRAF
V600E/MST1 null
mice was the frequent presence of muscle invasion (Figure 6I–L),




V600E constitutively activates the MEK-ERK signaling
pathway, promoting ERK-dependent transcriptional activity,
which regulates cell growth, cell proliferation, apoptosis evasion,
replicative potential, angiogenesis, and tissue invasion [44,45].
Figure 3. BRAF
V600E and MST1 kinases competitively regulate FoxO3 transactivation. (a,c) Co-transfection with 3X-IRS Luc (100 ng/well),
FoxO3 (0.5 mg/well), BRAF
V600E (indicated amount/well), MST1 (indicated amount/well), and/or SiMST1 (20 mM/well Stealth
TM RNA) was performed as
indicated. Twenty-four hours after transfection, a luciferase-based reporter assay was conducted. Total lysates were immunoblotted with anti-Myc,
anti-HA, anti-MST1, anti-BRAF, anti-Flag, or anti-Actin antibodies. All data are presented as mean6SD: (*) P,0.01 between two groups, Abbreviations:
CTL; control.
doi:10.1371/journal.pone.0016180.g003
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PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e16180RASSF1A primarily interacts with small GTPases such as Ras to
facilitate cell cycle arrest and apoptosis. Transcriptional silencing
of RASSF1A by promoter methylation has been reported in many
human cancers including thyroid cancer [46,47]. However,
epigenetic alteration has been regarded as a slow and time-
consuming process for gene silencing, implying that tumor
suppressors such as RASSF1A are inhibited to allow the initiation
and maintenance of oncogenic processes necessary for the
establishment of clinically significant thyroid cancers [48]. The
results of the present study suggest that BRAF
V600E tumors might
Figure 4. BRAF
V600E directly binds to the C-terminal domain of MST1 and represses MST1 kinase activity in vitro. (a–d) Co-transfection
with BRAF
V600E (1 mg/well), BRAF
WT (1 mg/well), Flag-MST1 (1 mg/well), Flag-MST1-N (1 mg/well), and Flag-MST1-C (1 mg/well) was performed as
indicated. Twenty-four hours after transfection, cells were lysed and the lysates were used for immunoprecipitation analyses with the indicated
primary antibodies. The immunoprecipitates were separated by SDS-PAGE and subjected to immunoblotting with anti-Flag or anti-BRAF antibodies.
(e) Co-transfection with BRAF
V600E (1 mg/well) and Flag-MST1 (indicated amount/well) was performed. Twenty-four hours after transfection,
immunoprecipitation of MST1 from cell lysates was performed and the washed precipitates were incubated for 30 minutes at 30uC with 1 mg histone
H2B in 25 mL kinase assay buffer. The reaction was terminated by the addition of Laemmli sample buffer and phosphorylated proteins were detected
by SDS-PAGE followed by autoradiography.
doi:10.1371/journal.pone.0016180.g004
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transfection induced p21 and p27 in a MST1-dependent manner,
suggesting that the RASSF1A-MST1-FoxO3 pathway can induce
cell cycle arrest. In addition, BRAF
V600E suppressed the
RASSF1A-MST1-mediated signal, inhibiting p21 and p27
induction, supporting the hypothesis of the present work. It has
been suggested that BRAF
V600E-activated ERK inhibits FoxO3 by
murine double minute 2 (MDM2)-mediated degradation [25].
However, BRAF
V600E did not alter HA-FoxO3 protein levels, as
shown by Western blot analysis, and, interestingly, treatment with
a MEK inhibitor did not abolish the BRAF
V600E-mediated
inactivation of FoxO3. In the present study, BRAF
V600E did not
induce phosphorylation of Akt/PKB and, furthermore, the
addition of PI3 kinase inhibitors did not affect the inhibition of
FoxO3 by BRAF
V600E. Therefore, BRAF
V600E did not affect
FoxO3 transactivation by a PI3-Akt/PKB-dependent signaling
Figure 5. BRAF
V600E affects FoxO3 mediated apoptotic gene expression. (a) 293 cells were transiently transfected with p27-promoter-luc
(0.1 mg/well) and Myc-FoxO3, and co-transfected with plasmids expressing Flag-MST1 as well as plasmids expressing BRAF
V600E. After 24 h, cells were
harvested and analyzed by Western blotting. (b) FRO cells were transiently transfected with Myc-FoxO3 and co-transfected with plasmids expressing
Flag-MST1 or BRAF
V600E as indicated.Total lysates were immunoblotted with the indicated antibodies. (c) MST1-FoxO-mediated apoptosis is reversed
by BRAF
V600E. 293T cells were transiently transfected with Myc-FoxO3 and co-transfected with Flag-MST1 as well as BRAF
V600E as indicated. After
24 hours, FoxO3 and MST-expressing cells were fixed and were then stained by the TUNEL protocol. TUNEL-positive cells (green) exhibit condensed or
fragmented DAPI-stained nuclei (blue), indicative of apoptosis. Quantification of the results is shown in the right panel. MST1 expression significantly
increased apoptosis, which is reduced by expression of BRAF
V600E. For each experiment at least 1000 cells were counted and analyzed by
Cellomics’sbioapplication. All data are presented as mean6SD.
doi:10.1371/journal.pone.0016180.g005
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activation [23]. In addition, the silencing of RAF-1, which has
been reported to bind with MST2, did not alter the inhibition of
FoxO3 transactivation by BRAF
V600E.Taken together,these data
suggest that FoxO3 inactivation might be a common process in the
carcinogenesis of PTC and that BRAF
V600E inhibits FoxO3
transactivation through a MEK-ERK–, Akt/PKB–, or RAF-1–
independent pathway. The results of the present study suggest the
existence of a novel FoxO3 inhibitory mechanism that might
operate in BRAF
V600E-induced PTC.
MST1 kinase had a counter-regulatory effect on FoxO3
activation and localization compared with Akt/PKB [49,50]. In
contrast to Akt/PKB, MST1 phosphorylation of FoxO3 promotes
its nuclear translocation, thereby inducing cell death [19]. A novel
inhibitory mechanism of FoxO3 transactivation might be opera-
tional in BRAF
V600E-induced PTC, which led to the evaluation of
BRAF
V600E regulation of MST1-FoxO3 signaling pathways. A
reporter assay revealed that MST1-induced FoxO3 transactivation
was completely inhibited by co-transfection with BRAF
V600E.I n
addition, over-expression of MST1 prevented BRAF
V600E-induced
FoxO3 inactivation. These data suggested that cross-regulation
between MST1 and BRAF
V600E might play a critical role in
regulating FoxO3 transactivation. Supporting this idea, immuno-
fluorescence studies revealed not only the BRAF
V600E-mediated
inhibition of MST1-induced FoxO3 nuclear translocation, but also
a direct interaction between MST1 and BRAF
V600E, which was
confirmed through IP assays that demonstrated that BRAF
V600E
binds to the C-terminal dimerization domain of MST1.
In fact, the dimerization domain of MST1/2 mediates MST1
kinase activity by interacting with binding partners such as
Figure 6. Microscopic features of Tg-BRAF
V600E/MST1 null mice. Thyroid tissues were fixed in 10% formalin and embedded in paraffin. Five
micrometer-thick sections were prepared and stained with H&E. At least five sections from each mouse were used for ImageJ analysis. Differences
between Tg-BRAF
V600E/MST1-null mice and Tg BRAF
V600E littermates were assessed by Mann-Whitney U-test. All data are presented as mean6SD. (a)
Representative figure from Tg-BRAF
V600E littermates shows characteristic features of human PTC, including nuclear enlargement, crowding and
overlapping (magnification610). (b&c) Representative immunohistochemical staining results with anti-cyclin D1 antibody in Tg-BRAF
V600E littermates
(b, magnification 610; c, magnification 6100). Circled area shows intensive staining of cyclin D1 and is magnified in c. (d) Numbers of
undifferentiated foci were calculated by counting the number of areas showing increased staining intensity of cyclin D1. (e) Representative image
from a Tg-BRAF
V600E/MST1 null mouse shows a limited area with follicle or colloid formation (e, magnification 610). (f,g) Representative
immunohistochemical staining results with anti-cyclin D1 antibody from a Tg-BRAF
V600E/MST1 null mouse, suggesting abundant undifferentiated foci
(f, magnification610; g, magnification6100). Circled areas show increased staining intensity of cyclin D1 and are magnified in g. (h) ImageJ analysis
of estimated areas without follicular architecture or colloid formation. Tg-BRAF
V600E/MST1 null mice (n=10) have larger areas than Tg-BRAF
V600E
littermates (n=10). (i,j) Representative images from a Tg-BRAF
V600E/MST1 null mouse show muscle invasion adjacent to the thyroid gland (f,
magnification640, boxed area is magnified and shown in j (magnification6100)). (k,l) Representative images from the other Tg-BRAF
V600E/MST1 null
mouse show aggressive invasion to muscle areas surrounding the upper pole of the thyroid gland (k, magnification640, boxed area is magnified and
presented at l (magnification 6100)). Arrows indicate invasive front in each figure. All data are presented as means6SD: (*) P,0.01; (**) P,0.05
between two groups.
doi:10.1371/journal.pone.0016180.g006
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MST1 activation and apoptosis via this hetero-dimerization, we
postulated that the direct interaction of MST1 with BRAF
V600E
might affect MST1 kinase activity. Actually, our in vitro kinase
assay clearly showed that MST1 kinase activity on histone H2B
was markedly decreased by BRAF
V600E. Another possible
mechanism of MST1 regulation may be the inhibitory phosphor-
ylation of MST1 by BRAF
V600E. Prior research has shown that
Akt/PKB can phosphorylate the Thr
387 residue of MST1 and
prevent its proteolytic activity, providing a mechanism for the
Akt/PKB-mediated inactivation of MST1-FoxO3 pathways [50].
Although the BRAF
V600E-induced MST1 phosphorylation was not
assessed, it remains possible that BRAF
V600E may phosphorylate
and inactivate MST1 through direct interaction with the C-
terminal domain of MST1.
Fewmousemodels existforthe studyoftumorsuppressor systems
in PTC. In the present study, a new in vivo model was generated to
investigate the cross-regulation between BRAF
V600E and MST1,
and the results obtained with transgenic mice were consistent with
the in vitro generated data. Although MST1 knockout mice did not
showany thyroidgland pathological changes comparedto wild-type
mice, Tg-BRAF
V600E/MST1 null mice showed an aggressive
phenotype, supporting the hypothesis that MST1 might have a
modifying effect on BRAF
V600E-induced carcinogenesis. Although
the lack of an appropriate antibody for the specific immunohisto-
chemical detection of serine207 residue in FOXO3 phosphorylated
by MST1 kinaseprevented the detection of FoxO3 activity modified
by MST1, these results, coupled with the results of in vitro assays,
suggest that BRAF
V600E may alleviate the tumor suppressor
function of RASSF1A-MST1 and vice versa.
In conclusion, the present study suggests that a direct
interaction between oncogenic BRAF
V600E and MST1 kinase
plays a crucial role in determining tumor behavior in PTC. This
novel interaction might provide advanced insight into the
pathogenesis of the disease, and form the basis for novel drug
development for the treatment of BRAF
V600E-induced PTC. In
light of this, it will be important to delineate the precise regulatory
mechanism of the RASSF1A-MST1 pathway and verify the action
of BRAF
V600E on this signal pathway in human PTC.
Supporting Information
Figure S1 MST1 significantly increases 3XIRS reporter activ-
ities. (A) 293T cells were cultured in 12 well dishes until they
reached 80% confluence, and co-transfected with 3XIRS Luc
(100 ng/well), FoxO3 (0.5 mg/well), and MST1 (0.5 mg/well) as
indicated for 24 hours. To verify transfection efficacy, total lysates
were immunoblotted with anti-HA, anti-Flag, and anti-Actin
antibodies. (B) Cells were co-transfected with 3XIRS Luc (100 ng/
well), FoxO3 (0.5 mg/well), and MST1 (indicated amount/well).
Total lysates were immunoblotted with anti-HA, anti-Flag, and
anti-Actin antibodies. For each sample, firefly luciferase activity
was normalized to Renilla luciferase activity and expressed as
relative-fold change compared to basal luciferase activity. All data
are presented as mean6SD: (*) P,0.01 between two groups.
(TIF)
Figure S2 BRAF
V600E inhibits MST1-induced nuclear translo-
cation of FoxO1. 293T cells were cultured in a six-well dish until
they reached 80% confluence and co-transfected with FoxO3-
GFP (0.5 mg/well), Flag-MST1 (0.5 mg/well), and Myc-
BRAF
V600E (0.5 mg/well) as indicated. Twenty-four hours after
transfection, the cells were prepared for subcellular fractionation
using the Nuclear/Cytosol Fractionation kit (BioVision, Inc. CA).
The markers, origin recognition complex subunit 1 (ORC1) and
b-tubulin, were used to verify the identity and purity of the nuclear
and cytosolic fractions, respectively. Based on these markers, a
good overall yield was obtained without mixing of the fractions.
(TIF)
Figure S3 BRAF
V600E mediated FoxO3 inhibition was not
altered by RAF-1. 293T cells were cultured in 12 well dishes until
they reached 80% confluence and co-transfected with 3XIRS Luc
(100 ng/well), FoxO3 (0.5 mg/well), BRAF
V600E (0.5 mg/well), and
SiRAF-1 (20 mM/well Stealth
TM RNA) for 24 h as indicated. Total
lysates were immunoblotted with anti-HA, anti-BRAF, anti-RAF-1,
and anti-Actin antibodies. For each sample, firefly luciferase activity
was normalized to Renilla luciferase activity and expressed as
relative-fold change compared to basal luciferase activity. All data
are presented as mean6SD: (*) P,0.01 between two groups.
(TIF)
Figure S4 BRAF
V600E suppresses FoxO3 transactivation via a
MEK/ERK-, PI3 kinase-independent pathway. 293T cells were
cultured in 12 well dishes until they reached 80% confluence, and
co-transfected with 3XIRS Luc (100 ng/well), FoxO3 (0.5 mg/
well), and BRAF
V600E (0.5 mg/well) as indicated for 24 h. MEK
inhibitor (lane 3, U0126 20 mM/well) and PI3 kinase inhibitors
(lane 4, Wortmannin 200 nM/well, and lane 5, LY294002
20 mM/well) were added. Total lysates were immunoblotted with
anti-HA, anti-BRAF, anti-pERK, anti-ERK, anti-pAkt/PKB,
anti-Akt/PKB, and anti-Actin antibodies. For each sample, firefly
luciferase activity was normalized to Renilla luciferase activity and
expressed as relative fold change compared to basal luciferase
activity. All data are presented as mean6SD. Abbreviations: U0,
U0126; WT, Wortmannin; LY, LY294002; and Con, control.
(TIF)
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